Cardiol Therapeutics Sets June 24 Date for Annual General Meeting
Shareholders of Cardiol Therapeutics will convene virtually on June 24, 2026, at 4:30 p.m. EDT to address company business. The Toronto-based life sciences firm, currently advancing late-stage clinical programs for heart disease, will host the meeting exclusively through a live online webcast for its investors.
Participants can access the meeting via the Lumi Connect platform. Detailed instructions regarding voting procedures and meeting participation are available through the investor relations portal on the company’s official website.
Cardiol Therapeutics continues to focus its research on CardiolRx, a small-molecule drug candidate targeting inflammation and fibrosis. The company is currently managing the MAVERIC program, which includes an ongoing Phase III trial for recurrent pericarditis, as well as development efforts for CRD-38, a novel subcutaneous formulation intended to treat inflammatory heart disease.
Comments (0)
No comments yet. Be the first!